Teva Pharmaceutical Fined €463 Million by EU for Market Manipulation: Company Accused of Delaying Generic Competition for Copaxone

The European Union's competition authority has imposed a hefty fine of €463 million ($503 million) on Teva Pharmaceuticals. The decision comes after findings that Teva exploited its dominant position in the European multiple sclerosis drug market to delay the introduction of competing generic versions of its flagship drug, Copaxone.

The investigation, which began in March 2021, revealed that Teva artificially extended the validity of patents protecting Copaxone to hinder competition. The company is also accused of disseminating misleading information regarding a generic version of the drug developed by a competitor, thus undermining market competition.

Teva Plans to Appeal
In response to the ruling, Teva has announced its intention to appeal the decision. The company expressed disappointment with the European Commission’s conclusions, arguing that the legal arguments made against it are unfounded and unsupported by factual evidence. Teva insists that it has cooperated fully with the Commission since 2019 and will vigorously defend its position in the appeal process.

Message to Pharmaceutical Companies
Margrethe Vestager, the director of the European Union's competition authority, stated that the fine serves as a clear warning to dominant pharmaceutical companies. She emphasized that the EU will not tolerate tactics aimed at blocking the entry of competing drugs into the market.

Impact on Teva's Revenue
Copaxone has been a major source of revenue for Teva, generating sales of $373 million in the EU in 2021 alone. The company’s acquisition spree over the past two decades was heavily reliant on the profitability of this drug, making the implications of this ruling significant for its future.

Commitment to Patients
Despite the challenges posed by the ruling, Teva remains committed to supporting patients with multiple sclerosis and their families. The company asserts that it conducts its business legally and ethically, maintaining its role as a vital partner for the EU, patient communities, and health systems across member states.

As the appeal process unfolds, the pharmaceutical industry will be watching closely to see how this case impacts both Teva and the broader landscape of competition within the sector.